Microchimica Acta

, Volume 102, Issue 1–3, pp 11–19 | Cite as

Kinetic study of Pt-cytostatics reactions by HPLC

  • Eva Brandšteterová
  • František Kiss
  • Stanislav Miertuš
  • Ján Garaj
Original Papers


HPLC with DAD (diode array detector) was applied as rapid method for the analytical control of the purity and stability of carboplatin and oxocarboplatin as effective cytostatics of 2nd generation. The stability of carboplatin has been measured in some infusion media (sodium chloride, glucose, sodium citrate) and compared to the cisplatin (cytostatic of 1st generation) stability. In addition ligand-exchange reactions between cisplatin and carboplatin have been studied together with the influence of temperature, pH and the concentrations of reactants. A method was developed for the analysis of clinical samples using solid-phase extraction as a preseparation and preconcentration step. The detection limits were 5 μg/ml serum for cisplatin, 0.16 μg/ml for carboplatin and 0.23 μg/ml for oxo-carboplatin.

Key words

cisplatin carboplatin HPLC determination solid-phase extraction serum analysis DAD detection 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    C. M. Riley, L. A. Sternson, A. J. Repta,J. Chromatogr. 1981,217, 405.Google Scholar
  2. [2]
    C. M. Riley, L. A. Sternson, A. J. Repta,J. Pharmacol. Sci. 1983,72, 351.Google Scholar
  3. [3]
    C. M. Riley, L. A. Sternson, A. J. Repta,J. Anal. Biochem. 1982,124, 167.Google Scholar
  4. [4]
    S. J. Banister, L. A. Sternson, A. J. Repta,J. Chromatogr. 1983,273, 301.PubMedGoogle Scholar
  5. [5]
    R. J. Knox, F. Friedlos, D. A. Lydall, J. J. Roberts,Cancer Res. 1986,46, 1972.PubMedGoogle Scholar
  6. [6]
    R. F. Greene, D. C. Chatterji, P. K. Hiranaka,Am. J. Hosp. Pharm. 1979,36, 38.PubMedGoogle Scholar
  7. [7]
    A. A. Hincal, D. F. Long, A. J. Repta,J. Parenter Drug Assoc. 1979,33, 107.PubMedGoogle Scholar
  8. [8]
    Y. W. Cheung, J. C. Cradock, B. B. Vishnuvajjala, K. P. Flora,Am. J. Hosp. Pharm. 1987,44, 124.PubMedGoogle Scholar
  9. [9]
    S. J. Hailand, D. R. Newell, Z. H. Siddik, R. Chadwick, A. H. Calvert, K. R. Harraz,Cancer Res. 1984,44, 1693.PubMedGoogle Scholar
  10. [10]
    R. C. Gaver, G. Deeb,Cancer Chemother. Pharmacol. 1986,16, 201.PubMedGoogle Scholar
  11. [11]
    I. S. Krull, X. D. Ding, S. Baverman, C. Selavka,J. Chromatogr. Sci. 1983,21, 166.PubMedGoogle Scholar
  12. [12]
    D. F. Long, A. J. Repta,Biopharm. Drug. Dispos. 1981,2, 1.PubMedGoogle Scholar
  13. [13]
    E. Segal, J. B. Pocq,Cancer Res. 1985,45, 492.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Eva Brandšteterová
    • 1
  • František Kiss
    • 2
  • Stanislav Miertuš
    • 1
  • Ján Garaj
    • 1
  1. 1.Department of Analytical ChemistrySlovak Technical UniversityBratislavaCzechoslovakia
  2. 2.Research Institute, LachemaBrnoCzechoslovakia

Personalised recommendations